190 related articles for article (PubMed ID: 21997189)
21. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation.
Doi K; Li R; Sung SS; Wu H; Liu Y; Manieri W; Krishnegowda G; Awwad A; Dewey A; Liu X; Amin S; Cheng C; Qin Y; Schonbrunn E; Daughdrill G; Loughran TP; Sebti S; Wang HG
J Biol Chem; 2012 Mar; 287(13):10224-10235. PubMed ID: 22311987
[TBL] [Abstract][Full Text] [Related]
22. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
Chen S; Dai Y; Harada H; Dent P; Grant S
Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
[TBL] [Abstract][Full Text] [Related]
23. p53-dependent regulation of Mcl-1 contributes to synergistic cell death by ionizing radiation and the Bcl-2/Bcl-XL inhibitor ABT-737.
Tagscherer KE; Fassl A; Sinkovic T; Combs SE; Roth W
Apoptosis; 2012 Feb; 17(2):187-99. PubMed ID: 22002102
[TBL] [Abstract][Full Text] [Related]
24. Acidosis promotes Bcl-2 family-mediated evasion of apoptosis: involvement of acid-sensing G protein-coupled receptor Gpr65 signaling to Mek/Erk.
Ryder C; McColl K; Zhong F; Distelhorst CW
J Biol Chem; 2012 Aug; 287(33):27863-75. PubMed ID: 22685289
[TBL] [Abstract][Full Text] [Related]
25. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
Lee EF; Czabotar PE; Yang H; Sleebs BE; Lessene G; Colman PM; Smith BJ; Fairlie WD
J Biol Chem; 2009 Oct; 284(44):30508-17. PubMed ID: 19726685
[TBL] [Abstract][Full Text] [Related]
26. Small molecule inhibition of the Bcl-X(L)-BH3 protein-protein interaction: proof-of-concept of an in vivo chemopotentiator ABT-737.
Stauffer SR
Curr Top Med Chem; 2007; 7(10):961-5. PubMed ID: 17508927
[TBL] [Abstract][Full Text] [Related]
27. Mcl-1 is an important therapeutic target for oral squamous cell carcinomas.
Maji S; Samal SK; Pattanaik L; Panda S; Quinn BA; Das SK; Sarkar D; Pellecchia M; Fisher PB; Dash R
Oncotarget; 2015 Jun; 6(18):16623-37. PubMed ID: 26009874
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of Bcl-2 family members sensitises soft tissue leiomyosarcomas to chemotherapy.
de Graaff MA; de Rooij MA; van den Akker BE; Gelderblom H; Chibon F; Coindre JM; Marino-Enriquez A; Fletcher JA; Cleton-Jansen AM; Bovée JV
Br J Cancer; 2016 May; 114(11):1219-26. PubMed ID: 27140314
[TBL] [Abstract][Full Text] [Related]
29. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
Hauck P; Chao BH; Litz J; Krystal GW
Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
[TBL] [Abstract][Full Text] [Related]
30. RNAi screening uncovers Dhx9 as a modifier of ABT-737 resistance in an Eμ-myc/Bcl-2 mouse model.
Mills JR; Malina A; Lee T; Di Paola D; Larsson O; Miething C; Grosse F; Tang H; Zannis-Hadjopoulos M; Lowe SW; Pelletier J
Blood; 2013 Apr; 121(17):3402-12. PubMed ID: 23440244
[TBL] [Abstract][Full Text] [Related]
31. Mitochondrial fragmentation and neuronal cell death in response to the Bcl-2/Bcl-x(L)/Bcl-w antagonist ABT-737.
Young KW; Piñón LG; Dhiraj D; Twiddy D; Macfarlane M; Hickman J; Nicotera P
Neuropharmacology; 2010 Jun; 58(8):1258-67. PubMed ID: 20307556
[TBL] [Abstract][Full Text] [Related]
32. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA
Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385
[TBL] [Abstract][Full Text] [Related]
33. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway.
Li R; Zang Y; Li C; Patel NS; Grandis JR; Johnson DE
Mol Pharmacol; 2009 May; 75(5):1231-9. PubMed ID: 19246337
[TBL] [Abstract][Full Text] [Related]
34. Mcl-1 and Bcl-x
Hockings C; Alsop AE; Fennell SC; Lee EF; Fairlie WD; Dewson G; Kluck RM
Cell Death Differ; 2018 Mar; 25(4):721-734. PubMed ID: 29459767
[TBL] [Abstract][Full Text] [Related]
35. The BH3 mimetic ABT-737 induces cancer cell senescence.
Song JH; Kandasamy K; Zemskova M; Lin YW; Kraft AS
Cancer Res; 2011 Jan; 71(2):506-15. PubMed ID: 21084274
[TBL] [Abstract][Full Text] [Related]
36. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
37. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice.
Grabow S; Delbridge AR; Valente LJ; Strasser A
Blood; 2014 Dec; 124(26):3939-46. PubMed ID: 25368374
[TBL] [Abstract][Full Text] [Related]
38. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1.
Wu H; Schiff DS; Lin Y; Neboori HJ; Goyal S; Feng Z; Haffty BG
Radiat Res; 2014 Dec; 182(6):618-25. PubMed ID: 25409124
[TBL] [Abstract][Full Text] [Related]
39. Caloric restriction modulates Mcl-1 expression and sensitizes lymphomas to BH3 mimetic in mice.
Meynet O; Zunino B; Happo L; Pradelli LA; Chiche J; Jacquin MA; Mondragón L; Tanti JF; Taillan B; Garnier G; Reverso-Meinietti J; Mounier N; Michiels JF; Michalak EM; Carles M; Scott CL; Ricci JE
Blood; 2013 Oct; 122(14):2402-11. PubMed ID: 23966420
[TBL] [Abstract][Full Text] [Related]
40. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells.
Allaman-Pillet N; Oberson A; Munier F; Schorderet DF
Ophthalmic Genet; 2013; 34(1-2):1-13. PubMed ID: 21955141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
